Meghan E Sise1, Elke Backman2, Guillermo A Ortiz3, Gregory L Hundemer3, Nneka N Ufere4, Donald F Chute4, Joseph Brancale4, Dihua Xu3, Jessica Wisocky5, Ming V Lin6, Arthur Y Kim7, Ravi Thadhani3, Raymond T Chung4. 1. Department of Medicine, Division of Nephrology, msise@partners.org. 2. Department of Pharmacy. 3. Department of Medicine, Division of Nephrology. 4. Department of Medicine, Gastrointestinal Unit, and. 5. Division of Gastroenterology, University of Massachusetts Medical Center, Worcester, Massachusetts; and. 6. Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts. 7. Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVES: Hepatitis C virus infection is common in patients with CKD and leads to accelerated progression to ESRD. Sofosbuvir is a potent direct-acting antiviral therapy against hepatitis C virus; however, there are concerns about its safety in patients with CKD. The objective of our study was to determine the safety and efficacy of sofosbuvir in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied a retrospective observational cohort of patients with CKD defined by eGFR<60 ml/min per 1.73 m2, ≥30 mg albuminuria per 1 g creatinine, or ≥200 mg proteinuria per 1 g creatinine who received sofosbuvir-based therapy in a large health care system. Regression models were constructed to predict likelihood of sustained virologic response, detect adverse events, and examine changes in eGFR from baseline to follow-up. RESULTS: Ninety-eight patients with CKD (42% stage 1 or 2 CKD and 58% stage 3 CKD) were included. Mean age was 62 years old, 78% were men, and 65% were white. Additionally, 49% of patients had diabetes, 38% of patients had cirrhosis, and 33% of patients had prior solid organ transplant. Overall sustained virologic response was 81% and varied by regimen used and viral genotype. Average baseline eGFR was equivalent to average on-treatment eGFR, but seven patients experienced a rise in creatinine ≥1.5 times baseline while taking sofosbuvir; all but one recovered. In patients with eGFR<60 ml/min per 1.73 m2 at baseline (stage 3 CKD), regression models showed that hepatitis C cure was associated with a 9.3 (95% confidence interval, 0.44 to 18) ml/min per 1.73 m2 improvement in eGFR during the 6-month post-treatment follow-up period. Adverse events were common (81%), but serious adverse events (17%) and treatment discontinuations (8%) were uncommon. CONCLUSIONS: Sofosbuvir-based direct-acting antiviral therapy is safe and effective in a cohort of patients with CKD infected with hepatitis C.
BACKGROUND AND OBJECTIVES:Hepatitis C virus infection is common in patients with CKD and leads to accelerated progression to ESRD. Sofosbuvir is a potent direct-acting antiviral therapy against hepatitis C virus; however, there are concerns about its safety in patients with CKD. The objective of our study was to determine the safety and efficacy of sofosbuvir in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied a retrospective observational cohort of patients with CKD defined by eGFR<60 ml/min per 1.73 m2, ≥30 mg albuminuria per 1 g creatinine, or ≥200 mg proteinuria per 1 g creatinine who received sofosbuvir-based therapy in a large health care system. Regression models were constructed to predict likelihood of sustained virologic response, detect adverse events, and examine changes in eGFR from baseline to follow-up. RESULTS: Ninety-eight patients with CKD (42% stage 1 or 2 CKD and 58% stage 3 CKD) were included. Mean age was 62 years old, 78% were men, and 65% were white. Additionally, 49% of patients had diabetes, 38% of patients had cirrhosis, and 33% of patients had prior solid organ transplant. Overall sustained virologic response was 81% and varied by regimen used and viral genotype. Average baseline eGFR was equivalent to average on-treatment eGFR, but seven patients experienced a rise in creatinine ≥1.5 times baseline while taking sofosbuvir; all but one recovered. In patients with eGFR<60 ml/min per 1.73 m2 at baseline (stage 3 CKD), regression models showed that hepatitis C cure was associated with a 9.3 (95% confidence interval, 0.44 to 18) ml/min per 1.73 m2 improvement in eGFR during the 6-month post-treatment follow-up period. Adverse events were common (81%), but serious adverse events (17%) and treatment discontinuations (8%) were uncommon. CONCLUSIONS:Sofosbuvir-based direct-acting antiviral therapy is safe and effective in a cohort of patients with CKD infected with hepatitis C.
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: Fred Poordad; William Sievert; Lindsay Mollison; Michael Bennett; Edmund Tse; Norbert Bräu; James Levin; Thomas Sepe; Samuel S Lee; Peter Angus; Brian Conway; Stanislas Pol; Nathalie Boyer; Jean-Pierre Bronowicki; Ira Jacobson; Andrew J Muir; K Rajender Reddy; Edward Tam; Grisell Ortiz-Lasanta; Victor de Lédinghen; Mark Sulkowski; Navdeep Boparai; Fiona McPhee; Eric Hughes; E Scott Swenson; Philip D Yin Journal: JAMA Date: 2015-05-05 Impact factor: 56.272
Authors: Saleh A Alqahtani; Nezam Afdhal; Stefan Zeuzem; Stuart C Gordon; Alessandra Mangia; Paul Kwo; Michael Fried; Jenny C Yang; Xiao Ding; Phillip S Pang; John G McHutchison; David Pound; K Rajender Reddy; Patrick Marcellin; Kris V Kowdley; Mark Sulkowski Journal: Hepatology Date: 2015-06-01 Impact factor: 17.425
Authors: Y Arase; K Ikeda; N Murashima; K Chayama; A Tsubota; I Koida; Y Suzuki; S Saitoh; M Kobayashi; M Kobayashi; M Kobayashi; H Kumada Journal: Intern Med Date: 1998-10 Impact factor: 1.271
Authors: Rachel B Fissell; Jennifer L Bragg-Gresham; John D Woods; Michel Jadoul; Brenda Gillespie; Sara A Hedderwick; Hugh C Rayner; Roger N Greenwood; Takashi Akiba; Eric W Young Journal: Kidney Int Date: 2004-06 Impact factor: 10.612
Authors: Apurva A Modi; Hector Nazario; James F Trotter; Manjushree Gautam; Jeffrey Weinstein; Parvez Mantry; Maisha Barnes; Adil Habib; Jean McAfee; Olga Teachenor; Lauren Tujague; Stevan Gonzalez Journal: Liver Transpl Date: 2016-03 Impact factor: 5.799
Authors: B J Brennan; K Wang; S Blotner; M O Magnusson; J J Wilkins; P Martin; J Solsky; K Nieforth; C Wat; J F Grippo Journal: Antimicrob Agents Chemother Date: 2013-09-30 Impact factor: 5.191
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem Journal: N Engl J Med Date: 2015-11-16 Impact factor: 91.245
Authors: Meghan E Sise; Donald F Chute; Yaa Oppong; Maya I Davis; Joshua D Long; Sakuni T Silva; Nifasha Rusibamayila; Deborah Jean-Francois; Syeda Raji; Sophia Zhao; Ravi Thadhani; Raymond T Chung Journal: Kidney Int Date: 2019-05-15 Impact factor: 10.612
Authors: Meghan E Sise; Ian Strohbehn; Donald Chute; Kathleen E Corey; Dahlene N Fusco; Venkata S Sabbisetti; Sushrut S Waikar; Raymond T Chung Journal: Hepatol Commun Date: 2020-06-04